News articles about Juniper Pharmaceuticals (NASDAQ:JNP) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Juniper Pharmaceuticals earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 47.0236214814285 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
JNP traded down $0.10 during midday trading on Friday, reaching $10.40. The company had a trading volume of 96,583 shares, compared to its average volume of 100,190. The company has a quick ratio of 1.81, a current ratio of 2.20 and a debt-to-equity ratio of 0.08. The stock has a market cap of $112.50, a price-to-earnings ratio of -69.33 and a beta of 0.46. Juniper Pharmaceuticals has a 12-month low of $3.65 and a 12-month high of $13.25.
Juniper Pharmaceuticals (NASDAQ:JNP) last posted its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.22. Juniper Pharmaceuticals had a negative net margin of 4.12% and a negative return on equity of 3.91%. The company had revenue of $11.79 million for the quarter, compared to analyst estimates of $16.00 million. sell-side analysts anticipate that Juniper Pharmaceuticals will post 3.5 earnings per share for the current year.
WARNING: This piece of content was first posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://baseballnewssource.com/2018/04/06/juniper-pharmaceuticals-jnp-receiving-somewhat-favorable-press-coverage-accern-reports/2037273.html.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.